APA (7th ed.) Citation

LAH, B., AEM, K., LCW, v. d. W., R, L., DM, B., & A, C. (2024). Correction: Relative Bioavailability of Dolutegravir (DTG) and Emtricitabine/Tenofovir Alafenamide Fumarate (F/TAF) Administered as Paediatric Tablet Formulations in Healthy Volunteers. Clinical pharmacokinetics, 63(5), 729. https://doi.org/10.1007/s40262-024-01378-z

Chicago Style (17th ed.) Citation

LAH, Bevers, Kamphuis AEM, van der Wekken-Pas LCW, Leisegang R, Burger DM, and Colbers A. "Correction: Relative Bioavailability of Dolutegravir (DTG) and Emtricitabine/Tenofovir Alafenamide Fumarate (F/TAF) Administered as Paediatric Tablet Formulations in Healthy Volunteers." Clinical Pharmacokinetics 63, no. 5 (2024): 729. https://doi.org/10.1007/s40262-024-01378-z.

MLA (9th ed.) Citation

LAH, Bevers, et al. "Correction: Relative Bioavailability of Dolutegravir (DTG) and Emtricitabine/Tenofovir Alafenamide Fumarate (F/TAF) Administered as Paediatric Tablet Formulations in Healthy Volunteers." Clinical Pharmacokinetics, vol. 63, no. 5, 2024, p. 729, https://doi.org/10.1007/s40262-024-01378-z.